Related references
Note: Only part of the references are listed.Safety, tolerability and pharmacokinetics after single and multiple doses of preladenant (SCH420814) administered in healthy subjects
D. L. Cutler et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2012)
Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial
Robert A. Hauser et al.
LANCET NEUROLOGY (2011)
Adverse Events from the Treatment of Parkinson's Disease
Kelvin L. Chou
NEUROLOGIC CLINICS (2008)
Potent, selective, and orally active adenosine A2A receptor antagonists:: Arylpiperazine derivatives of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines
Bernard R. Neustadt et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2007)
Share Paper
